Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Xbrane Biopharma AB (DE:7XB)
BERLIN:7XB
Holding DE:7XB?
Track your performance easily
7XB Stock Chart & Stats
Day’s Range― - ―
52-Week Range€0.01 - €0.21
Previous CloseN/A
Volume0.00
Average Volume (3M)1.80K
Market Cap
€20.58M
Enterprise Value€438.01M
Total Cash (Recent Filing)$31.34M
Total Debt (Recent Filing)$1.73M
Price to Earnings (P/E)―
Beta2.94
Next Earnings
Feb 21, 2025EPS Estimate
<0.01Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.09
Shares Outstanding1,529,483,400
10 Day Avg. Volume450
30 Day Avg. Volume1,801
Standard DeviationN/A
R-SquaredN/A
AlphaN/A
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)40.07
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market Cap21.28
Enterprise Value/Revenue7.60
Enterprise Value/Gross Profit7.60
Enterprise Value/Ebitda-2.64
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
Xbrane Biopharma AB News
7XB FAQ
What was Xbrane Biopharma AB’s price range in the past 12 months?
Xbrane Biopharma AB lowest stock price was €0.01 and its highest was €0.21 in the past 12 months.
What is Xbrane Biopharma AB’s market cap?
Xbrane Biopharma AB’s market cap is €20.58M.
When is Xbrane Biopharma AB’s upcoming earnings report date?
Xbrane Biopharma AB’s upcoming earnings report date is Feb 21, 2025 which is in 37 days.
How were Xbrane Biopharma AB’s earnings last quarter?
Xbrane Biopharma AB released its earnings results on Oct 24, 2024. The company reported -€0.003 earnings per share for the quarter, missing the consensus estimate of >-€0.001 by -€0.002.
Is Xbrane Biopharma AB overvalued?
According to Wall Street analysts Xbrane Biopharma AB’s price is currently Overvalued.
Does Xbrane Biopharma AB pay dividends?
Xbrane Biopharma AB does not currently pay dividends.
What is Xbrane Biopharma AB’s EPS estimate?
Xbrane Biopharma AB’s EPS estimate is <0.01.
How many shares outstanding does Xbrane Biopharma AB have?
Xbrane Biopharma AB has 1,529,483,400 shares outstanding.
What happened to Xbrane Biopharma AB’s price movement after its last earnings report?
Xbrane Biopharma AB reported an EPS of -€0.003 in its last earnings report, missing expectations of >-€0.001. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Xbrane Biopharma AB?
Currently, no hedge funds are holding shares in DE:7XB
---
Company Description
Xbrane Biopharma AB
Xbrane Biopharma AB is a biopharmaceutical company, develops and manufactures biosimilars and generic long-acting injectables. It offers products including Spherotide, a long-acting injectable with the active substance triptorelin for the treatment of prostate cancer, breast cancer, endometriosis, and myoma and Xlucane, a ranibizumab biosimilar for the treatment of age-related macular degeneration, diabetes-related macular edema, diabetic retinopathy, and retinal vein occlusion. The company has two segments that are Biosimilars and Long-acting Injectables and Administration and unallocated.
---
Technical Analysis
---